Identifying hyperinsulinaemia in the absence of impaired glucose tolerance: An examination of the Kraft database

Diabetes Research and Clinical Practice

Volumn 118, Issue , 2016, Pages 50-57

  Crofts, Catherine ^a   Schofield, Grant ^a   Zinn, Caryn ^a   Wheldon, Mark ^a   Kraft, Joseph ^b  

^a AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

^b SAINT JOSEPH HOSPITAL   (United States)

Author keywords

Diabetes; Hyperinsulinaemia; Insulin; Oral glucose tolerance test

Indexed keywords

GLUCOSE; INSULIN; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESPONSE; KRAFT DATABASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OBESITY; RISK FACTOR; SCREENING TEST; BLOOD; FACTUAL DATABASE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HYPERINSULINISM; ILLINOIS; INCIDENCE; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED;

BLOOD GLUCOSE; DATABASES, FACTUAL; FASTING; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERINSULINISM; ILLINOIS; INCIDENCE; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84975885992     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2016.06.007     Document Type: Article

References (38)

1. [1] Crofts, C., et al. Hyperinsulinaemia: a unifying theory of chronic disease?. Diabesity 1:4 (2015), 34–43.
2. [2] Kelly, C.T., et al. Hyperinsulinemic syndrome: the metabolic syndrome is broader than you think. Surgery 156:2 (2014), 405–411.
3. [3] Samaras, K., et al. Insulin levels in insulin resistance: phantom of the metabolic opera?. Med J Aust, 185(3), 2006, 159.
4. [4] Stout, R.W., Insulin and atheroma: 20-yr perspective. Diabetes Care 13:6 (1990), 631–654.
5. [5] Giovannucci, E., et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 60:4 (2010), 207–221.
6. [6] Maher, P.A., Schubert, D.R., Metabolic links between diabetes and Alzheimer's disease. Expert Rev Neurother 9:5 (2009), 617–630.
7. [7] Rask-Madsen, C., King, G.L., Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 3:1 (2007), 46–56.
8. [8] Bayir, H., Reactive oxygen species. Crit Care Med 33:12 (2005), S498–S501.
9. [9] Pollak, M., Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:12 (2008), 915–928.
10. [10] Monzo, H.J., et al. Insulin and IGF1 modulate turnover of polysialylated neuronal cell adhesion molecule (PSA-NCAM) in a process involving specific extracellular matrix components. J Neurochem, 2013.
11. [11] Qiu, W.Q., Folstein, M.F., Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer's disease: Review and hypothesis. Neurobiol Aging 27:2 (2006), 190–198.
12. [12] Dankner, R., et al. Basal-state hyperinsulinemia in healthy normoglycemic adults is predictive of type 2 diabetes over a 24-year follow-up: a preliminary report. Diabetes Care 32:8 (2009), 1464–1466.
13. [13] Mehran, Arya E., et al. Hyperinsulinemia drives diet-induced obesity independently of brain insulin production. Cell Metab 16:6 (2012), 723–737.
14. [14] Ludwig, D.S., Friedman, M., Increasing adiposity: consequence or cause of overeating. JAMA 311:2 (2014), 2167–2168.
15. [15] Medina-Santillán, R., et al. Hepatic manifestations of metabolic syndrome. Diabetes/Metab Res Rev, 2013.
16. [16] Widjaja, A., et al. Within- and between-subject variation in commonly measured anthropometric and biochemical variables. Clin Chem 45:4 (1999), 561–566.
17. [17] Kraft, J.R., Detection of diabetes mellitus in situ (occult diabetes). Lab Med 6:2 (1975), 10–22.
18. [18] Kraft, J.R., Diabetes epidemic and you. 2nd ed., 2011, Trafford, Victoria, BC.
19. [19] Passey, R.B., et al. Evaluation and comparison of 10 glucose methods and the reference method recommended in the proposed product class standard (1974). Clin Chem 23:1 (1977), 131–139.
20. [20] World Health Organization, Definition, diagnosis and classification of diabetes mellitus and its complications. 1999, World Health Organization, Geneva.
21. [21] McAuley, K.A., et al. Diagnosing insulin resistance in the general population. Diabetes Care 24:3 (2001), 460–464.
22. [22] Ghani, R.A., et al. The influence of fasting insulin level in post-gestational diabetes mellitus women receiving low-glycaemic-index diets. Nutr Diab, 4, 2014, e107.
23. [23] Laakso, M., How good a marker is insulin level for insulin resistance?. Am J Epidemiol 137:9 (1993), 959–965.
24. [24] Kraft, J.R., Glucose/insulin tolerance. A routine clinical laboratory tool enhancing diabetic detection. Radioassay: Clinical concepts, 1974 Washington. D.C.
25. [25] Weir, G.C., Bonner-Weir, S., Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 53:suppl 3 (2004), S16–S21.
26. [26] Hayashi, T., et al. Patterns of insulin concentration during the OGTT predict the risk of type 2 diabetes in Japanese Americans. Diabetes Care 36:5 (2013), 1229–1235.
27. [27] Qatanani, M., Lazar, M.A., Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev 21:12 (2007), 1443–1455.
28. [28] Odeleye, O.E., et al. Fasting hyperinsulinemia is a predictor of increased body weight gain and obesity in Pima Indian children. Diabetes – Am Diab Assoc 46:8 (1997), 1341–1345.
29. [29] Ning, F., et al. Development of coronary heart disease and ischemic stroke in relation to fasting and 2-hour plasma glucose levels in the normal range. Cardiovasc Diabetol, 11(1), 2012, 76.
30. [30] Abdul-Ghani, M.A., et al. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the veterans administration genetic epidemiology study. Diabetes 55:5 (2006), 1430–1435.
31. [31] Gordon, B., et al. Reproducibility of multiple repeated oral glucose tolerance tests. Diabetes Res Clin Pract 94:3 (2011), e78–e82.
32. [32] Ogden, C.L., Carroll, M.D., Prevalence of overweight, obesity and extreme obesity among adults: United States, trends 1960–1962 through 2007–2008. 2010, National Centre for Health Statistics.
33. [33] Centers for Disease Control and Prevention. Number (in millions) of civilian, noninstitutionalized persons with diagnosed diabetes, United States, 1980–2011. 2013 [cited 2015 28 April]; Available from: http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm.
34. [34] Kirk, J.K., et al. Restricted-carbohydrate diets in patients with type 2 diabetes: a meta-analysis. J Am Diet Assoc 108:1 (2008), 91–100.
35. [35] Feinman, R.D., et al. Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base. Nutrition 31:1 (2015), 1–13.
36. [36] Kahn, C.R., Chen, L., Cohen, S.E., Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 106:11 (2000), 1305–1307.
37. [37] Chilelli, N.C., Burlina, S., Lapolla, A., AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a “glycoxidation-centric” point of view. Nutr Metab Cardiovasc Dis, 2013.
38. [38] Purcell, G.V., Behenna, D.B., Walsh, P.R., Evaluation of the BMC glucose oxidase/peroxidase-4-aminophenazone-phenol procedure for glucose as adapted to the Technicon SMAC. Clin Chem 25:10 (1979), 1844–1846.